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Rearrangements  in  MLL  (MLL-r)  are  common  within  very  young  children  with  leukemia  and  affect  the
prognosis  and  treatment.  Previous  studies  have  suggested  the  use  of the  NG2  molecule  as  a marker  for
MLL-r  but  these  studies  were  performed  using  a small  number  of infants.  We  analyzed  148  patients  (all
less  than  24  months,  86 less  than  12 months)  from  various  centers  in  Brazil  to  determine  the predictive
power  of NG2  within  that cohort.  We  show  that  NG2  can  be  used for  MLL-r  prediction;  however,  propereywords:
cute lymphoblastic leukemia
cute  myeloid leukemia
mmunophenotype
nfant  leukemia
staff  training  and  standardized  sampling  procedures  are  essential  when  receiving  samples  from  multiple
centers  as the  accuracy  of  the prediction  varies  greatly  on  a per  center  basis.
© 2011 Elsevier Ltd. Open access under the Elsevier OA license.LL
G2
. Introduction
Rearrangements involving the myeloid–lymphoid lineage (MLL)
ene on chromosome band 11q23 are frequent in both lymphoid
nd myeloid leukemia [1,2]. These genetic aberrations constitute
n indicative characteristic for etiology and prognosis as patients
ith MLL-AFF1 (MLL-AF4) fusion are subjected to the high-risk pro-
ocol especially when the onset occurs in the ﬁrst year of life (infant
eukemia, IL) [3]. For this reason, the accurate detection of MLL rear-
angements (MLL-r)  is crucial when dealing with this aggressive
ype of leukemia. Currently used methods to detect these rear-
angements include conventional cytogenetics, ﬂuorescence in situ
ybridization (FISH) and reverse transcription-PCR (RT-PCR) anal-
ses and long distance inverse PCR [4–8]. With the discovery in
umans of a homolog of the cell surface chondroitin sulfate NG2
olecule in rats, previous groups have reported that MLL-r  may
e predicted through the cell surface recognition of NG2 using the
onoclonal antibody (MoAb) 7.1 [9–12]. The mechanisms under-
ying this association are still being examined [13] and a lack of
ssociation has been reported in certain cases [14]. Due to the
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0231-050, Rio de Janeiro/RJ, Brazil. Tel.: +55 21 3207 6606; fax: +55 21 3207 6505.
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Open access under the Elsevier OA license.fact that MLL-r detection using standard techniques can be costly
and requires specialized skills, a rapid and cost-effective technique
would be quite useful especially for developing countries [15].
Some  studies, while trying to determine the optimal pro-
cedure to maximize sensitivity and speciﬁcity upon using the
immunophenotipic NG2 criterion for predicting MLL-r,  concluded
that immunophenotyping is a reliable tool for the prediction of
MLL-r [15,16]. However these results were obtained using samples
where infant patients were under-represented despite the fact that
this subgroup represents the vast majority of leukemia patients
with MLL-r [1,17].
In  this study, we analyzed the value of NG2 detection in predict-
ing MLL-r in acute leukemia cells using a large cohort of IL patients
enrolled in the Brazilian Collaborative Study Group of Infant Acute
Leukemia (BCSGIAL). The data was  collected by various medical
centers scattered across Brazil. While using all of the patient data as
a single set casts doubt on the use of NG2 as an adequate marker for
MLL-r, an analysis performed on a per center basis indicates other-
wise. We  show that great discrepancies exist between the qualities
of the results for each center thus showing that proper caution
must be taken upon use of the NG2 marker for MLL diagnostic espe-
cially for countries with uneven levels of regional development.
Despite this, since the technique shows great predictive power for
certain centers, we  can conclude that NG2 is an adequate predictor
of MLL-r given that the sampling and handling were performed
correctly.
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.  Materials and methods
.1. Patients
Patient cohort consists of children at age ≤24 months that were diagnosed with
cute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) between Jan-
ary 2003 and July 2010. Initial dataset contained samples from 311 patients, all
f  which were diagnosed with acute leukemia during this period. Out of those,
e  retained 148 patients for our study based on the available results for NG2
7.1) immunophenotyping. To examine possible bias introduced by selecting study
atients, we compared the clinical characteristics for patients studied herein and
ll  ascertainable ones. No statistical difference was  found between study patients
nd all BCSGIAL ascertained cases as far as gender, age, and MLL-r are concerned
p  > 0.05, data not shown). The laboratory received samples from 35 different medi-
al  centers scattered across Brazil [18]. The time from the samples’ collection to the
mmunophenotypic analysis varied between 8 and 36 h depending on the distance
etween the sampling center and our institute. The referring physicians provided
emographic and clinical information like place of birth, age, gender, white blood
ell (WBC) count, sample collection date, medication use, etc. Both data collec-
ion and laboratory procedures have been evaluated and approved by the Ethics
ommittee of all included institutions.
.2. Leukemia diagnosis
The diagnosis was initially established by clinical examination and morpholog-
cal characteristics of lymphoid and myeloid cells according to standard criteria.
he samples were collected with ethylenediaminetetraacetic acid (EDTA) and sent
o  the laboratory in Rio de Janeiro for immunophenotyping. Mononuclear cells
ere isolated from bone marrow (BM) using Ficoll–Hystopaque (Sigma, Steinheim,
ermany) density gradient centrifugation. Cell counting was  performed using an
utomated cell counter (CELM, São Paulo, Brazil), which aspirates 20 L of WBC
iluted in phosphate buffered saline (PBS) + 15% fetal bovine serum (the equip-
ent is able to count between 0.0 and 199.9 × 106 cells/mL). The mononuclear
ellular viability has been assessed through propidium iodide staining (Sigma, St
ouis, USA) and the stained cells were visualized in Neubauer chamber; all samples
ncluded in this analysis presented at least 70% of viable cells. Immunophenotyping
f  BM aspirates was  performed at diagnosis using panel of MoAbs recommended
y the European Group for the Immunological Characterization of Leukemias (EGIL)
19].  Fluorochrome-labeled MoAbs were used in triplet staining experiments, using
uorescein isothiocyanate (FITC), phycoerythrin (PE) and PE-cyanine 5 (PECy5) ﬂu-
rochrome conjugates in each tube. Cell samples were analyzed by ﬂow cytometry
ACSCalibur (Becton, Dickinson and Company, CA, USA) using the Cell-Quest soft-
are program. Cell surface antigens were considered positive when 20% or more
ells showed ﬂuorescence intensity greater than the negative control while the
utoff for cytoplasmic antigen aMPO was  10%. Depending on the immunophe-
otype of BM cells, the patients were assigned to different categories: B-lineage
able 1
emographical and laboratorial characteristics of patients.
Categoriesa n(%) MLL(+)(%)
AFF1 MLLT3
Age (months)
0–12 85 (57.4) 19 (70.4) 6 (60)
13–24  63 (42.6) 8 (29.6) 4 (40)
Subtype
ALL  subtype 95(64.2)
pro-B 46 (48.4) 17 (63) 3 (30)
Common 36 (37.9) 5 (18.5) 2 (20)
pre-B 3  (3.2) 0 1 (10)
pro-T  6 (6.3) 0 0 
Otherb 4 (4.2) 1 (3.7) 0 
AML  53 (35.8) 4 (14.8) 4 (40)
CD10  expressionc
Positive 41 (33.1) 6 (27.3) 2 (25)
Negative 83 (66.9) 16 (72.7) 6 (75)
7.1  Expressiond
Positive 63 (42.6) 20 (74.1) 6 (60)
Negative 85 (57.4) 7 (25.9) 4 (40)
WBC  count
≤50,000 60 (40.5) 6 (22.2) 5 (50)
>50,000 88 (59.5) 21 (77.8) 5 (50)
Total  148 (100) 
LL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; NK, not known; WBC,
a 3 Cases of ALL and 11 cases of AML  could not be subclassiﬁed.
b Includes 3 cases with unknown subtype and one case with biphenotypic acute leukem
c In 24 samples CD10 expression was not analyzed.
d Qualitative analysis.search 35 (2011) 1001– 1007
ALL, T-lineage ALL, AML, and biphenotypic and the presence of genetic abnormali-
ties commonly observed in childhood leukemias (ETV6-RUNX1, E2A-PBX1, BCR-ABL,
AML1-ETO, CBFB-MYH11) was ascertained according to BIOMED-1 Concerted Action
[8].
2.3. Qualitative and quantitative NG2 immunophenotyping
The presence of NG2 chondroitin sulfate proteoglycan molecule was evaluated
using the CD34FITC/7.1PE/CD45PECy5 MoAb combinations; 10 L of monoclonal
antigen NG2 (7.1) (Immunotech) 1/20 diluted was  used in each tube. Qualitative
analysis was  based on negative or positive signals while quantitative analysis was
based on quantiﬁed molecules of equivalent soluble ﬂuorescein (MESF) values.
2.4. Cytogenetic and molecular analyses
Detection of MLL-r were performed either by conventional cytogenetics, reverse
transcriptase PCR, and/or by FISH technique (LSI MLL  Dual Color Break Apart Rear-
rangement Probe, Vysis Inc.) as previously described [5].
2.5. Statistical analysis
The database of the qualitative (negative, low, bright signals) and quantitative
(MESF) data has been analyzed using standard univariate procedure. To compare the
frequency of NG2 positivity between different groups (e.g. age strata, ALL vs AML
patients, CD10-positive vs CD10-negative, MLL-r vs MLL-germline) the 2-test (two-
sided) was  used (or Fisher’s exact P-values with sets with very few data points).
A  P-value of less than 0.05 was considered statistically signiﬁcant. All statistical
analyses were done with the package IBM SPSS Statistics 14.0 version (Chicago, Il.).
2.6. Computational methods
The accuracy scores and the receiver operating characteristic (ROC) curves were
produced with the ROCR package [20] using R version 2.10.1. We manually separated
our sampling centers according to the observed correlation between the quantitative
and qualitative NG2 measurements and MLL-r into 3 groups: centers with correlated
data, centers with uncorrelated data (Table 3) and centers for which too few data
points to reach a conclusion (Supplementary Table 1). Data points for which the MLL
status could not be ascertained (5 cases out of 148) were removed from the analysis.
3. ResultsEighty-ﬁve out of 148 (57.4%) were ≤12 months-old while the
remaining were aged between 13 and 24 months-old. The majority
of samples showed >50.000 WBC  count (59.5%) as shown in Table 1.
The leukemia subtype classiﬁcation was successfully performed in
 MLLT1 NK Total
 6 (85.7) 13 (81.3) 44 (73.3)
 1 (14.3) 3 (18.7) 16 (26.7)
 2 (28.6) 10 (62.5) 32 (53.3)
 2 (28.6) 1 (6.3) 10 (16.7)
 0 0 1 (1.7)
2 (28.6) 0 2 (3.3)
0 0 1 (1.7)
 1 (14.2) 5 (31.2) 14 (23.3)
 2 (28.6) 3 (25) 13 (26.5)
 5 (71.4) 9 (75) 36 (73.5)
 2 (28.6) 10 (62.5) 38 (63.3)
 5 (71.4) 6 (37.5) 22 (36.7)
 1 (14.3) 3 (18.7) 15 (25)
 6 (85.7) 13 (81.3) 45 (75)
60 (100)
 white blood cell.
ia.
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Table  2
Accuracy values for qualitative and quantitative ﬂow cytometry.
Qualitative FC Quantitative FC
Overall patients (n = 143)
Best cutoff 20 61.34
Accuracy 0.678 0.720
ALL  (n = 92)
Best cutoff 22 39.1
Accuracy 0.695 0.750
AML  (n = 51)
Best cutoff Inﬁnitya Inﬁnity
Accuracy 0.725 0.725
Time until diagnosis
<12 h (n = 15)
Best cutoff 34 92.76
Accuracy 0.93 1.00
>12  h (n = 128)
Best cutoff 20 39.1
Accuracy 0.65 0.69
Previous corticoid use
Yes (n = 14)
Best cutoff 56 98.8
Accuracy 0.785 0.714
No  (n = 129)
Best cutoff 20 39.1
Accuracy 0.666 0.728
MLL  detection by FISH (n = 35)
Best cutoff 7 27.38
Accuracy 0.800 0.714
FC, ﬂow cytometry; ALL, acute lymphoblastic leukemia; AML, acute myeloid
leukemia; FISH, ﬂuorescent in situ hybridization.
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aa An inﬁnity value means that the algorithm labeled everything as being MLL-r;
his indicates that the correlation is so poor that the best prediction that can be
ade involves marking every element in the set as being MLL-r.
34 out of 148 (90.5%) samples as 3 cases of ALL and 11 cases of AML
ould not be subclassiﬁed. Within the ALL cases (n = 95), Bp-ALL
nd T-ALL represented 89.5% and 6.3%, respectively. Forty-six ALL
ases displayed the CD10-negative pro-B ALL immunophenotype
48.4%), whereas the remaining cases were common ALL (n = 36) or
re-B ALL (n = 3). AML  cases represented 35.8% of the total series,
nd M4/M5  accounted for the majority (62%) of AML  cases. A dia-
ram representing our series of patients is shown in Supplementary
ig. 3.
able 3
ccuracy table for qualitative and quantitative ﬂow cytometry separating by sets of instit
Center n QL FC QT
(total; pos; neg) Best cutoff Accuracy Bes
All uncorrelated centers 63;29;34 91.00 0.556 71.
Goiânia, GO 6;3;3 ∞ 0.500 ∞ 
Ponta  Grossa, PR 2;2;0 N/A N/A N/A
Florianópolis, SC 5;0;5 N/A N/A N/A
João  Pessoa, PB 8;1;7 ∞ 0.875 44.
Campina Grande, PB 2;1;1 ∞ 0.500 ∞ 
Recife, PE 6;4;2 2.00 0.833 1.1
Salvador, BA 29;17;12 0.00 0.586 71.
Itabuna, BA 5;1;4 ∞ 0.800 ∞ 
All  correlated centers 56;22;34 34.00 0.857 39.
Salvador, BA 3;0;3 N/A N/A N/A
Brasília, DF 11;5;6 8.00 1.000 40.
Salvador, BA 8;2;6 34.00 1.000 61.
Rio  de Janeiro, RJ 6;3;3 65.00 1.000 105
Curitiba, PR 2;1;1 37.00 1.000 ∞ 
Campo Grande, MS 11;3;8 46.00 0.909 41.
São  Paulo, SP 3;0;3 N/A N/A N/A
Teresina, PI 4;3;1 7.00 1.000 20.
Rio  de Janeiro, RJ 8;5;3 16.00 0.875 21.
he columns labeled “best cutoff” represent the cutoff that maximizes overall accuracy wh
n  previous studies. A “N/A” indicates that we were unable to ﬁnd an adequate cutoff due
lgorithm labeled everything as being MLL-r. n, Number of cases; pos, positive; neg, negasearch 35 (2011) 1001– 1007 1003
In 143 out of 148 ALL cases (96.6%) the presence or absence of an
MLL-r could be analyzed. The molecular analysis showed an MLL-r
in 60 patients, 44 (73.3%) of which were found within infants (≤12
months). Within MLL-r positive cases, 27 patients (45%) had MLL-
AFF1 fusion gene transcripts, 10 (16.7%) had MLL-MLLT3 (MLL-AF9)
fusion gene transcripts, 7 (11.7%) had MLL-ENL (MLL-MLLT1) fusion
gene transcripts, and 16 (26.6%) had unknown MLL partner genes.
Cases with these three translocations with known partner genes
accounted therefore for about 73% of all MLL-r leukemia samples.
Within the 27 MLL-AFF1 cases, 4 presented the AML  subtype
and 23 patients had the ALL subtype. Immunophenotype analy-
sis in the different MLL groups revealed that 17 out of 23 (73.9%)
ALL cases with MLL-AFF1 were pro-B-ALL (CD10-negative). The only
ﬁve c-ALL (CD10-positive) MLL-AFF1-positive cases were found
in patients who  were all older than 16 months old at diagnosis.
MLL-MLLT1 and MLL-MLLT3 infants were predominantly pro-B-ALL
(CD10-negative) whereas MLL-germline cases were mainly CD10-
positive. All patients with a fusion partner other than AFF1, MLLT3
or MLLT1 were CD10-negative. CD10-positive patients were signif-
icantly older at diagnosis as compared to CD10-negative patients
(Mann–Whitney U-test, p < 0.05).
As expected from the association with MLL-r, NG2-positive cases
were over-represented within the ≤12 months group and sig-
niﬁcantly associated with hyperleukocytosis and central nervous
system involvement, with CD10-immunophenotype and myeloid-
associated antigens expression (p < 0.05). While in ALLs, NG2
positivity correlated with pro-B immunophenotype, in AMLs, the
positivity correlated with myelomonocytic cell differentiation.
Twenty out of 27 (74.1%) MLL-AFF1 positive patients were NG2-
positive (qualitative analysis, cutoff 20%) while 8 out of 17 (47%)
evaluable patients with other known MLL-r (MLL-MLLT1 and MLL-
MLLT3) other than MLL-AFF1 were NG2-positive. MLL-r patients had
a signiﬁcantly lower CD10 expression than MLL-germline patients
(median 1.5% versus 3.5%, U test, p < 0.0001).
Accuracy values for the ability of NG2 to detect MLL-r were cal-dividing this set according to a number of variables (Table 2). In the
overall analysis, accuracy values were 0.67 and 0.72 for qualitative
and quantitative methods, respectively (Tables 2 and 3 and Fig. 1).
Although the set with previous corticoid use yielded better results
utes.
 FC QL FC with cutoff = 20 QT FC with cutoff = 400
t cutoff Accuracy Accuracy Accuracy
77 0.635 0.524 0.556
0.500 0.500 0.333
 N/A N/A N/A
 N/A N/A N/A
38 1.000 0.625 1.000
0.500 0.000 0.000
9 0.667 0.667 0.500
77 0.621 0.517 0.448
0.800 0.200 0.600
10 0.839 0.804 0.679
 N/A N/A N/A
18 1.000 1.000 0.818
34 1.000 0.750 0.875
.92 1.000 0.667 0.667
0.500 0.500 0.000
63 0.818 0.727 0.636
 N/A N/A N/A
36 1.000 0.750 0.500
03 0.875 0.875 0.500
ile the remaining ones represent the data with the cutoffs that have been reported
 to the scarcity or unevenness of data while an inﬁnity symbol (∞) means that the
tive; QL, qualitative; FC, ﬂow cytometry; QT, quantitative.
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F  rearrangements. A – Qualitative analysis. B – Quantitative analysis. C – Random analysis
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Table 4
Accuracy table for qualitative and quantitative results according to time until sample
processing.
NG2a
Qualitative MESF
Time till analysis < 12 h n = 15
True positive ratio 100 100
True negative ratio 87.5 100
False positive ratio 12.5 0
False negative ratio 0 0
Sensitivity 100 100
Speciﬁcity 87.5 100
Positive predictive value 87.5 100
Negative predictive value 100 100
Accuracy 93.3 100
Time till analysis > 12 h n = 128
True positive ratio 58.5 50.9
True  negative ratio 70.6 82.6
False positive ratio 29.3 17.3
False negative ratio 41.5 49
Sensitivity 58.4 50.9
Speciﬁcity 70.6 82.6
Positive predictive value 58.4 67.5
Negative predictive value 70.6 70.4
Accuracy 65.6 69.5ig. 1. ROC curves displaying the accuracy of the NG2 molecule for predicting MLL
nd  D – MLL detected by gold-standard method. AUC, area under the curve.
han the one without such use (Supplemental Fig. 1), an unequiv-
cal conclusion cannot be made due to the scarcity of data points
ithin that given set. While separating by leukemic subtypes (ALL
s AML), we noticed that the accuracy of NG2 in detecting leukemic
ells with MLL-r was higher in ALL cases than AML cases (Table 2
nd Supplemental Fig. 2).
To evaluate whether the time until sample analysis could inﬂu-
nce the predictive power of NG2, we separated our dataset into
he ones for which the BM aspirate collection had been processed
ithin less than 12 h and those for which that time was greater
han 12 h. We  observed that, despite the small number of cases
ith a processing time of less than 12 h (15 in total), the accu-
acy of the method (0.93 and 1.00 for qualitative and quantitative
ethods, respectively) was signiﬁcantly greater than the accuracy
hat had previously been obtained using the whole dataset (Table 2
nd Fig. 2). However, we observed that certain geographical regions
ere over-represented within the dataset containing samples with
ess than 12 h until analysis. To ascertain whether the origin of the
amples had any impact on our results, we proceeded to evaluate
he predictive power of quantitative and qualitative NG2 measure-
ents and MLL-r on a per center basis. The results showed that
he accuracy differed signiﬁcantly between them (Table 4). Despite
he fact that some centers provided an uneven number of samples,
e grouped data from various centers according to whether there
as a signiﬁcant level of correlation between NG2 measurements
nd MLL-r for the samples they provided. The results indicate that
rouping centers with high levels of correlations and those poor
evels of correlation and subsequently performing the analysis on
he clustered data shows great disparity with the use of NG2 as a
arker for MLL-r (Fig. 3).MESF, molecules of equivalent soluable ﬂuorescein.
a Results were generated based on best cutoff values.4. Discussion
Solid diagnosis of MLL-r in pediatric patients is highly deter-
minative in therapy stratiﬁcation. The use of ﬂow cytometry, a
M.  Emerenciano et al. / Leukemia Research 35 (2011) 1001– 1007 1005
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vig. 2. ROC curves displaying the accuracy of the NG2 molecule for predicting ML
hose  processed within >12 h. AUC, area under the curve.
idely accepted diagnostic tool to identify these rearrangements,
as been pointed out to be particularly relevant in low-income
ountries. Worldwide efforts have focused on achieving high sen-
itivity and speciﬁcity values using FC to identify MLL-r [15,16].
owever, no study has analyzed the use of this procedure in the
ow-income scenario for which many variables may  inﬂuence the
nal results, especially in Brazil, a country with continental char-
cteristics. The BCSGIAL has succeeded in collecting a substantial
umber of IL samples which have been well characterized through
mmune-molecular methods [18].
Thus, this is the ﬁrst study that investigates the accuracy of NG2
n the detection of leukemic cells of both myeloid and lymphoid
ineages with MLL-r using such a large number of early childhood
ases. Furthermore, we report our efforts to determine which vari-
bles could inﬂuence the ﬁnal results.
MLL-r in pediatric acute leukemias can occur with at least 64
artner genes with more than 100 possible breakpoints. These dif-
erent partner genes may  be categorized according to their gene
ntology into functional subclasses [2] which may  reﬂect distinct
igniﬁcances. We  found a higher correlation between MLL-AFF1 and
he expression of NG2 than when comparing with other rearrange-
ents. Other studies have also reported divergent NG2 reactivity
n acute leukemia cells with different MLL-r [10–13] indicating that
ifferent NG2 expression patterns may  depend on the particular
ranslocation partner gene.Accuracy values for our entire cohort of patient were 0.67
nd 0.72 for qualitative and quantitative analysis, respectively. As
xpected from the results of previous studies, we also found better
rediction values in ALL cases than AML  [9–12]. It is known that the
ariability of MLL  partner genes is more frequent among AML  casesangements while separating samples processed within <12 h from collection and
[2] therefore, this may  also be an explanation for the difference in
accuracy between ALL and AML  samples.
The accuracy values increased signiﬁcantly while using samples
processed within less than 12 h and became on par with the one
reported by previous studies [5–9]. Consequently, further analysis
was performed by separating the data according to the institute ori-
gin of the samples. Upon noticing that the accuracy varied greatly
between institutes, we  compiled a list of institutes for which the
samples provided adequate accuracy and those with lesser correla-
tion. Since samples were collected in various institutes but analysis
was performed in a single central institute, the observed discrep-
ancy alludes to the inconsistency of the quality of the collection
procedures on a per center basis. Ideally, both collection and anal-
ysis should occur within a core diagnostic center, however, this may
not be realistic in a very large and heterogeneous country such as
Brazil.
We also evaluated the city and state where the contributing
institutes are located since one idiosyncratic aspect that can be
observed in Brazil is the stark differences in the level of develop-
ment between various regions. For instance, the Federal District
with a Human Development Index (HDI) of 0.900 is on par with the
Czech Republic whereas Alagoas, a small state in the north-east,
has an HDI of 0.722, comparable with Equatorial Guinea [21,22].
These regional differences can be observed in our data as well. Using
the list of correlated sets and uncorrelated ones, we observed that
79% of the data (stemming from 5 different centers out of a total
of 8) in uncorrelated sets came from states with a medium HDI
(less than 0.799). In contrast, 6 out of the 9 correlated sets (repre-
senting 73% of the data in those sets) originated from states with
a high HDI (greater than 0.800). These discrepancies in accuracy
1006 M. Emerenciano et al. / Leukemia Research 35 (2011) 1001– 1007
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he  curve.
an likely be explained by the differences between the quality of
he reagents and staff training. As Zangrando et al. alluded to, a
ast and reliable test for MLL  is especially useful for developing
ountries. However, our results highlight that in developing coun-
ries with great regional differences in development like Brazil, care
ust be taken in predicting MLL-r using ﬂow-cytometry especially
hen the samples come from multifarious sources stemming from
egions with dissimilar levels of development. Despite this, we  can
lso observe that the separation is somewhat ambiguous as we see
ets collected in regions with a lesser levels of development within
he reliable ones. This reassuring thought indicates that even cen-
ers in low-income regions can, with proper training and reagents,
roduce data that can be readily used for diagnostic.
Another factor to be examined is the adequate cutoff that sepa-
ates patients as having an MLL-r from those that do not. Previous
tudies have reported the use of 20% for qualitative and 400 for
uantitative as reasonable cutoffs for NG2 ﬂow cytometry. In con-
rast, a recent study [23] evaluating the use of CD9 expression
o predict ETV6-RUNX1-positive ALL has reported that cutoffs for
mmunophenotyping markers can be tailored to maximize differ-
nt measures of association. Similarly, upon looking at the cutoff for
aximizing the overall accuracy, we ﬁrst notice that the optimal
utoff is not necessarily the aforementioned one used in the lit-
rature and, perhaps more importantly, the optimal cutoffs seem
o vary from center to center. These results indicate that, despite
he fact that NG2 seems an appropriate marker for MLL-r, greater
tandardization must be implemented in the collection procedure
nd additional work is needed to ﬁnd the cutoff that minimizes as
uch as possible the false negative rate while keeping a relatively
ow false positive rate.gements while separating samples according to institute of origin. AUC, area under
5.  Conclusions
Our results suggest that immunophenotyping is a reliable
approach to predict MLL-r using both subjective (gating processes
by qualitative approach) and objective (MESF values by quanti-
tative approach) FC methods on NG2 antigen data. However, in
low-income regions, there might be some factors that ultimately
lead to a lower accuracy.
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